SQW commissioned to evaluate Data to Early Diagnosis and Precision Medicine ISCF Challenge
The Data to Early Diagnosis and Precision Medicine (D2EDPM) Challenge was announced as part of the Life Sciences Sector Deal in late 2017. UKRI is providing a significant investment of £210m through the Industrial Strategy Challenge Fund over five years from 2017/18 to 2022/23.
The Challenge has three main themes: large-scale whole genome sequencing; digital pathology, in-vivo imaging and enabling integrated diagnostics; and a Digital Innovation Hub programme. A further £50m in DHSC capital investment has been invested by the Office for Life Sciences in three of the digital pathology and radiology centres of excellence.
The long-term objectives of the D2EDPM Challenge are to: accelerate the development of data driven healthcare technologies for clinical use; develop centres of excellence/clusters of high-quality diagnostic, digital health and precision medicine focused companies; support the growth of the UK’s precision medicine sector; and increase efficiencies in the NHS.
In 2020, an SQW led consortium was commissioned to evaluate the D2EDPM Challenge. The consortium includes PHG Foundation, Impact Data Metrics, ADL and IFF Research. The evaluation aims to assess both the impact of the D2EDPM Challenge and the process through which it is delivered. We have produced an Evaluation Framework and are currently finishing the baseline research. In autumn 2021 we will undertake progress and process evaluation before we carry out the impact evaluation of the Challenge in early 2023.